EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Praziquantel – 50 Years of Research

Andreas Waechtler, Bertram Cezanne iD, David Maillard iD, Rui Sun, Shaofang Wang, Jihua Wang, Achim Harder

ChemMedChem · 15.06.2023 · 18 (12)

DOI: 10.1002/cmdc.202300154 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 18.04.2023. Verfasst von Andreas Waechtler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Central Process Development Department (EL-OTS) Merck KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany. Hauptthemen laut MEDLINE: TRPM Cation Channels, Schistosomiasis. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: Bill & Melinda Gates Foundation, Global Health Innovative Technology Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Investigations on praziquantel (PZQ) started fifty years ago by a cooperation between Bayer AG and Merck KGaA. Until today PZQ is the drug of choice for schistosomiasis in human medicine and used in many combinations with antinematode drugs in veterinary medicine. The Sm.TRPM PZQ , a Ca 2+ ‐permeable transient receptor potential (TRP) channel, has been discovered as primary target of PZQ during the last decade. Furthermore, there is a short overview of routes of large‐scale synthesis of racemic and pure (R)‐ PZQ. Until now racemic PZQ is used in veterinary and human medicine. In 2012 the Pediatric Praziquantel Consortium started PZQ chemistry and process development of pure (R)‐ PZQ for human application. It is hoped that (R)‐ PZQ will become available for pediatric use soon. The knowledge of the binding pocket of PZQ in Sm.TRPM PZQ allows to design synthesis of PZQ‐derivatives of the next generation for a target‐site directed screening. A similar screening should also be started for Fasciola hepatica TRPM PZQ .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TRPM Cation ChannelsSchistosomiasisHumansChildPraziquantel

Stichwörter der Autor:innen

Mechanism of actionPraziquantel (PZQ)SchistosomiasisSm.TRPMPZQSynthesis Strategies

Substanzen

PraziquantelTRPM Cation Channels

Autor:innen und Institutionen

  • Central Process Development Department (EL-OTS) Merck KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany.
  • R&D Department, Valiant Pharmaceutical Co. Ltd., Taiyuan Road No. 60, YEDA, Yantai, Shandong, 264006, China.
  • Technical Department, Valiant Corporation Ltd., Wuzhishan Road No. 11, YEDA, Yantai, Shandong, 264006, China.
  • Department WE Biology, Institute of Biology, Heinrich-Heine University Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany.

ORCID-Profile: Bertram Cezanne, David Maillard

Förderung

  • Bill & Melinda Gates Foundation
  • Global Health Innovative Technology Fund

Zitieren

APA

Waechtler, A., Cezanne, B., Maillard, D., Sun, R., Wang, S., Wang, J., & Harder, A. (2023). Praziquantel – 50 Years of Research. ChemMedChem, 18(12). https://doi.org/10.1002/cmdc.202300154

Vancouver

Waechtler A, Cezanne B, Maillard D, Sun R, Wang S, Wang J, et al. Praziquantel – 50 Years of Research. ChemMedChem. 2023;18(12). doi:10.1002/cmdc.202300154

BibTeX
@article{Waechtler2023,
  author = {Waechtler, Andreas and Cezanne, Bertram and Maillard, David and Sun, Rui and Wang, Shaofang and Wang, Jihua and Harder, Achim},
  title = {Praziquantel – 50 Years of Research},
  journal = {ChemMedChem},
  year = {2023},
  volume = {18},
  number = {12},
  doi = {10.1002/cmdc.202300154}
}
Kostenlos starten →